Navigation Links
UV Flu Technologies Outlines Distribution and Expansion Plans for 2013
Date:12/12/2012

while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.)  The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange C
'/>"/>

SOURCE UV Flu Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
2. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
3. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
4. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
5. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
6. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
7. BioStorage Technologies to Lead Discussion on the Value of a Comprehensive Sample Management Strategy
8. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
9. MedClean Technologies Announces 2011 Results
10. Patient Safety Technologies Reports First Quarter 2012 Results
11. Breathe Technologies Non-Invasive Open Ventilation (NIOV™) System Receives Medical Design Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... 2012  JARVIK HEART, Inc., a privately-held company that develops ... of its Pivotal Trial for evaluation of the Jarvik ... device for DT means that it will provide long-term, ... are not candidates for heart transplant. The approval permits ...
... Feb. 27, 2012 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited ... and marketer of medical devices worldwide, announced today its ... full year ended December 31, 2011. ... Fourth quarter net revenue increased 25.2% year-over-year ...
Cached Medicine Technology:JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy 2JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy 3Mindray Announces 2011 Fourth Quarter and Full Year Results 2Mindray Announces 2011 Fourth Quarter and Full Year Results 3Mindray Announces 2011 Fourth Quarter and Full Year Results 4Mindray Announces 2011 Fourth Quarter and Full Year Results 5Mindray Announces 2011 Fourth Quarter and Full Year Results 6Mindray Announces 2011 Fourth Quarter and Full Year Results 7Mindray Announces 2011 Fourth Quarter and Full Year Results 8Mindray Announces 2011 Fourth Quarter and Full Year Results 9Mindray Announces 2011 Fourth Quarter and Full Year Results 10Mindray Announces 2011 Fourth Quarter and Full Year Results 11Mindray Announces 2011 Fourth Quarter and Full Year Results 12Mindray Announces 2011 Fourth Quarter and Full Year Results 13Mindray Announces 2011 Fourth Quarter and Full Year Results 14Mindray Announces 2011 Fourth Quarter and Full Year Results 15Mindray Announces 2011 Fourth Quarter and Full Year Results 16Mindray Announces 2011 Fourth Quarter and Full Year Results 17
(Date:4/24/2014)... often coexist with the negative and stressful outcomes for ... diagnosed with a life-limiting illness, says a recent study ... , While the challenges are numerous and life-changing and ... participated in the Waterloo-led research reported positive outcomes as ... appear in the most recent issue of the ...
(Date:4/24/2014)... in the new Institute for Biomedical Sciences at ... million federal grant to develop novel therapeutics against ... from the Eunice Kennedy Shriver National Institute Of ... Institutes of Health will support Plemper,s drug development ... least one distinct alternative compound. , Infections by ...
(Date:4/24/2014)... Ill. It is better to give than to receive ... giving, a new study suggests. , The study found that ... as giving their money to family members, are less likely ... from taking risks or keeping the money for themselves. , ... the National Academy of Sciences . , The study focused ...
(Date:4/24/2014)... influenza pH1N1 virus caused the first flu pandemic in ... 2009 and killed more than 50 people in the ... during flu epidemics (winter/spring seasons). , Infections with ... illnesses. World Health Organization has recommended Tamiflu for treatment ... of this drug is that it targets viral proteins ...
(Date:4/23/2014)... say clinical trials for a new experimental drug ... promising. Patients treated with CPX-351, a combination of ... better responses than patients treated with the standard ... leukemia is an aggressive blood cancer with very ... patients," explained Jeffrey Lancet, M.D., senior member of ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2
... LANSING, Mich. To tackle the growing number of psychiatric cases ... team of Michigan State University doctors from the colleges of ... from across the state via video conference. , On ... see up to 10 patients each from as far away ...
... study says , , MONDAY, Oct. 27 (HealthDay News) -- ... coronary conditions, might reduce the effect of the clot-preventing ... blockers appear to inactivate an enzyme essential for the ... published online Oct. 28 in the Journal of ...
... Treatment, ST. LOUIS, Oct. 27 Leading ... deliver radioactive seed therapy,in the prostate. The innovative ... the prostate during procedures. With the gland stabilized,physicians ... to map,and confirm placement of radiation., Unveiled ...
... Study found desires remained essentially unchanged over 3-year period ... declines in either mental or physical health, most senior ... want their end-of-life care to be when the time ... that despite observing an overall stability in patient perspective, ...
... Oct. 27 SpectraCell Laboratories, Inc.,announced that ... facilities. Recently,SpectraCell occupied a 20,000 sq. ft. ... 2005. The planned expansion added a second ... campus. The new $3.5 million facility houses,SpectraCell,s ...
... an initial,step in the creation of a wellness ... it has acquired HealthMedia, Inc., a,privately held company ... change interventions. Terms of the transaction were not,disclosed., ... to,effectively emulate a health coach via the web. ...
Cached Medicine News:Health News:MSU doctors bring much-needed psychiatric care to rural areas via technology 2Health News:Common Heart Drugs May Hamper Blood Thinner 2Health News:Common Heart Drugs May Hamper Blood Thinner 3Health News:Doctors Test Advanced Tool for Treating Prostate Cancer 2Health News:Seniors Tend to Stick With End-of-Life Care Preferences 2Health News:Seniors Tend to Stick With End-of-Life Care Preferences 3Health News:SpectraCell Laboratories Expands Operations in New Facility 2Health News:Johnson & Johnson Establishes Wellness & Prevention Platform with Acquisition of HealthMedia, Inc. 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: